VARIZIG (Cangene BioPharma)


Welcome to the PulseAid listing for the VARIZIG drug offered from Cangene BioPharma. This pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.

LABELER NAME / MANUFACTURER: Cangene BioPharma
NON-PROPRIETARY NAME: Varicella Zoster Immune Globulin (Human)
SUBSTANCE NAME: HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN
TYPE: PLASMA DERIVATIVE
PHARMA CLASS:
ROUTE: INTRAMUSCULAR
DOSAGE FORM: LIQUID
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2015-05-22
END MARKETING DATE: 0000-00-00


VARIZIG PLASMA DERIVATIVE Details:

Item DescriptionVARIZIG from Cangene BioPharma
LABELER NAME: Cangene BioPharma
DEA SCHEDULE:
ACTIVE STRENGTH: 1.25([iU]/mL)
START MARKETING DATE: 2015-05-22
END MARKETING DATE: 0000-00-00
PRODUCT ID: 53270-0126_1743d54c-b53e-4a93-9bcb-41caf047fc10
PRODUCT NDC: 53270-0126
APPLICATION NUMBER: BLA125430

Other HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Aptevo BioTherapeutics LLCVARIZIG
Cangene BioPharmaVARIZIG